Skip to main content

RocketVax raises fresh capital

| News

RocketVax raises fresh capital


The Basel-based biotech startup RocketVax has successfully closed another financing round. This additional funding will primarily be used to further develop a second-generation vaccine to combat the SARS-CoV-2 virus.

RocketVax AG has successfully raised further capital after closing a financing round, which was led by the Foundation of Urs and Simone Wietlisbach. The foundation acquired a 9 percent stake in RocketVax as well. Urs Wietlisbach is the co-founder of the Partners Group, a Zug-based investment firm.

According to a press release, the additional funding will above all be put towards further developing a second-generation vaccine against the SARS-CoV-2 virus. “Despite the very difficult environment, we have managed to secure reputable investors who have invested significant amounts”, comments Dr. Vladimir Cmiljanovic, Vice President of RocketVax, before adding: “We still believe that the RocketVax vaccine is urgently needed”.

Partnership with Basel-based institutions

The Basel-based biotech startup was founded in 2020 as a subsidiary of the startup incubator and accelerator Swiss Rockets AG. The company operates on the basis of a collaboration between Swiss Rockets, Gigabases Switzerland AG, a spin-off from the Swiss Federal Institute of Technology in Zurich (ETH), the University Hospital of Basel, ETH Zurich itself, the University of Zurich and the University of Basel, as well as the Swiss Tropical and Public Health Institute. It is working in parallel on the development of three live attenuated vaccines. Two of these COVID-19 serums are slow replicating SARS-CoV-2 viruses, while the third is based on a genetically engineered SARS-CoV-2 virus that cannot replicate.

The advantage of these is that they not only protect the immune system by producing spike antibodies, but also generate a wide range of other antibodies and T cells. According to RocketVax, this should provide longer-lasting protection against wild-type viruses and virus variations. In addition, the vaccine is said to be very stable at ambient temperatures, which should also allow it to be administered to people in warmer and poorer countries.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

biGENIUS receives 2 million euros for new cloud product

Software company biGENIUS, based in the Basel Area, has secured financing of 2 million euros. This funding was granted following...
Read More

Opterion Health secures investment of 6.5 million Swiss francs

Opterion Health has raised a total of 6.5 million Swiss francs as part of a financing round. The company, which...
Read More

TOLREMO receives 39 million US dollars in investments

TOLREMO Therapeutics has concluded a series A funding round with 39 million US dollars. The biotech company based in Basel...
Read More

Mazars opens tenth Swiss office in Basel

Mazars is now also present in Basel with a subsidiary as of September 1. This is the tenth Swiss location...
Read More

Medtech in Switzerland – bringing together traditional skills and hightech industry

How the intersection of traditional and novel skillsets in the Jura area is propelling Switzerland into a new era of...
Read More

Fondation Botnar supporting further research into pediatric health

The Basel-based Botnar Research Centre for Child Health has received a further donation of 50 million Swiss francs from the...
Read More

Do you have a question? We'd like to hear from you.